Berry Genomics Co. Ltd. Class A 000710

SZSE · China · Health Technology

CNY 10.87+0.99 (+10.02%)

Market closed· Sep 30, 2026, 7:04 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Berry Genomics Co. Ltd. Class A 000710

SZSE · China · Health Technology

CNY 10.87+0.99 (+10.02%)

Market closed· Sep 30, 2026, 7:04 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

+4.12% · 6MFull-screen chart

Open CNY 9.92High CNY 10.87Low CNY 9.92Close CNY 10.87Volume 25.24M

Sep 30, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: CNY 9.88
Day range: CNY 9.92 – CNY 10.87
52-week range: CNY 7.20 – CNY 15.63
Volume: 25.34M
Market cap: CNY 3.83B
Avg. volume (1Y): 14.33M

Performance

1 week

+8.59%

1 month

+21.86%

3 months

+38.47%

6 months

+5.43%

Year to date

-10.02%

1 year

-16.19%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: China
Exchange: SZSE
Shares outstanding: 353.52M
Employees: 1,331
ISIN: CNE000000PN7
Beta: 1.15

Technical view

Above averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceOct 20, 2025

China DNA Sequencing Research Report 2025: Market to Reach $3.1 Billion by 2030, Dominated by BGI, Novogene, Berry Genomics, Annoroad Gene Technology, and Burning Rock Dx

The Chinese DNA sequencing market is expanding rapidly due to rising demand for precision medicine, technological advancements, and government investments. Key opportunities lie in oncology diagnostics, reproductive health, infectious disease surveillance, and large-scale genomics, driven by companies like BGI and Novogene.Dublin, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The "The Chinese Market for DNA Sequencing" report has been added to ResearchAndMarkets.com's offering. The Chinese DNA sequencing ma

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.